Search results for "Medication"

showing 10 items of 322 documents

Metformin and contrast-induced acte kidney injury in diabetic patients treated with primary percutaneous coronary intervention for ST segment elevati…

2016

IF 4.638; International audience; AIM : To analyze the association between chronic metformin treatment and the development of contrast-induced acute kidney injury (CI-AKI) after primary percutaneous coronary intervention (PCI) for ST segment elevation myocardial infarction (STEMI).METHODS: Patients with type 2 diabetes mellitus (T2DM) treated with PCI 27μmol/l (0.3mg/dl) or >50% over baseline after PCI. Since PCI was urgent, metformin could not be withheld prior to PCI but was usually stopped after PCI.RESULTS:Among the 372 patients included, 147 (40%) were using metformin, which had older diabetes, but had risk factors similar to patients without metformin. Baseline eGFR was better in pati…

Malemedicine.medical_specialtyendocrine system diseasesMedication Therapy Managementmedicine.medical_treatmentStatistics as TopicContrast Media030204 cardiovascular system & hematologyCoronary AngiographyRisk Assessment03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsST segment030212 general & internal medicineMyocardial infarctioncardiovascular diseasesAgedbusiness.industryPrimary percutaneous coronary interventionAcute kidney injuryPercutaneous coronary interventionnutritional and metabolic diseasesMiddle Aged[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism[ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.diseaseST segment elevation segment myocardial infarctionMetformin3. Good healthMetforminAcute kidney injuryDiabetes Mellitus Type 2CreatinineConventional PCICardiologyST Elevation Myocardial InfarctionFemaleFranceCardiology and Cardiovascular MedicinebusinessKidney diseasemedicine.drug
researchProduct

Perioperative nonspecific histamine release : a new classification by aetiological mechanisms and evaluation of their clinical relevance

1993

As a consequence of the performance of a randomized controlled clinical trial on perioperative histamine release and cardiovascular and respiratory disturbances, several types of increases in plasma histamine had to be distinguished instead of only two which existed at the beginning of the study: drug-induced allergic and pseudoallergic reactions. First of all, the new classification by aetiology (clinical epidemiology) was derived from a meta-analysis (secondary analysis) of the most recent literature. According to that histamine release in the perioperative period has several, different causes and is involved in several, different disease manifestations. A clear distinction (classificatio…

AdultMaleHistamine ReleaseDrug HypersensitivityIntraoperative Periodchemistry.chemical_compoundHumansMedicineAnesthesiaClinical significanceProspective StudiesAgedAnestheticsNeurosecretionbusiness.industryGeneral MedicinePerioperativeMiddle AgedPathophysiologyAnalgesics OpioidClinical trialAnesthesiology and Pain MedicinechemistryAnesthesiaEtiologyGastric acidFemalePremedicationNeuromuscular Blocking AgentsbusinessHistamineHistamineAnnales Françaises d'Anesthésie et de Réanimation
researchProduct

A pragmatic window of opportunity to minimise the risk of MRONJ development in individuals with osteoporosis on Denosumab therapy: a hypothesis

2021

Abstract Denosumab is associated with the development of medication-related osteonecrosis of the jaw (MRONJ), an uncommon but severe oral side effect with a higher prevalence in metastatic cancer patients than in patients with metabolic bone fragility. Although several oral triggers can initiate MRONJ, invasive oral treatments and tooth extraction still remain the most common precipitating event. In general, tooth extraction and oral surgery should be avoided in patients at increased risk of MRONJ, while extraction of non-restorable teeth should be performed based on specific risk reduction protocols to eliminate dental/periodontal infections, still protecting from MRONJ onset. Based on th…

medicine.medical_specialtySide effectOsteoporosisSpecialties of internal medicine030209 endocrinology & metabolismMRONJOral surgery tooth extraction03 medical and health sciences0302 clinical medicineOral surgeryMedication-related osteonecrosis of the jawmedicineDenosumab osteoporosis; Medication-related osteonecrosis of the jaw; MRONJ; Oral surgery tooth extraction; Denosumab; Diphosphonates; Humans; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; OsteoporosisHumansIntensive care medicineGeneral Dentistrytooth extractionBisphosphonate-associated osteonecrosis of the jawDiphosphonatesBone Density Conservation Agentsbusiness.industryHypothesismedicine.diseaseosteoporosisDenosumab osteoporosisBone Density Conservation Agentsstomatognathic diseasesDenosumabOtorhinolaryngologyRC581-951030220 oncology & carcinogenesisDental surgeryOral and maxillofacial surgeryBisphosphonate-Associated Osteonecrosis of the JawNeurology (clinical)DenosumabbusinessOsteonecrosis of the jawmedicine.drugHead & Face Medicine
researchProduct

Pharmacokinetics of new oral anticoagulants: implications for use in routine care

2018

Introduction: Since 2008, new oral anticoagulants (NOACs) have been approved for the prevention of venous thromboembolism (VTE) in patients receiving hip or knee replacement surgery, prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF), treatment of deep vein thrombosis (DVT), and pulmonary embolism (PE). Premarketing randomized clinical trials (RCTs) of NOACs demonstrated their non-inferiority in terms of efficacy vs. warfarin (traditional oral anticoagulant–TOA), with lower risk of serious adverse drug reactions, especially cerebral hemorrhages. In clinical practice, pharmacokinetic aspects of NOACs have to be carefully taken into account to …

medicine.medical_treatmentnew oral anticoagulantsAdministration OralKnee replacement030204 cardiovascular system & hematologyToxicologyAdherence Bleeding Interactions New oral anticoagulants Over- and under-dosage Persistence Pharmacokinetics Real World Evidence0302 clinical medicineAtrial Fibrillationover- and underdosage030212 general & internal medicinepharmacokineticStrokeRoutine careRandomized Controlled Trials as Topicnew oral anticoagulantAtrial fibrillationpersistenceVenous ThromboembolismGeneral MedicinePulmonary embolismStrokepharmacokineticsHumanmusculoskeletal diseasesmedicine.medical_specialtyinteractionHemorrhageMedication Adherence03 medical and health sciencesPharmacokineticsmedicineHumansReal World EvidenceIn patientOver- and under-dosagecardiovascular diseasesreal-world evidenceIntensive care medicineAgedPharmacologybusiness.industryAnticoagulantAnticoagulantsinteractionsbleedingmedicine.diseaseAdherencePulmonary EmbolismbusinessVenous thromboembolismExpert Opinion on Drug Metabolism & Toxicology
researchProduct

Description of the response of a new multi-parametric brain sensor to physiological and pathophysiological challenges in the cortex of juvenile pigs

2014

AIM Monitoring of intracranial pressure (ICP), local cerebral blood flow (CBF) and oxygen is part of modern intensive critical care medicine. Preclinical evaluation of newly developed catheters that should monitor several parameters simultaneously is reported poorly in the literature. The goal of our study was (1) to evaluate a new multi-parametric sensor in brain tissue and (2) to establish a testing protocol using pathophysiological challenges that target measured parameters of the sensor and autoregulatory boundaries and could be used as preclinical standard protocol in future studies. MATERIAL AND METHODS We describe data from 12 new multi-parametric brain sensors (MPBS) that were impla…

Cerebral CortexCardiac outputIntracranial PressureSwinebusiness.industryOxygenationHypoxia (medical)Neurophysiological MonitoringNorepinephrine (medication)Oxygen ConsumptionBlood pressureClinical ProtocolsCerebral blood flowCerebrovascular CirculationmedicineAnimalsSurgeryNeurology (clinical)medicine.symptombusinessHypercapniaNeuroscienceIntracranial pressureBiomedical engineeringmedicine.drugTurkish Neurosurgery
researchProduct

Attitudes toward Different Formulations of Psychotropic Drugs

2006

Attitudes toward psychotropic drug treatment are likely to be a factor in medication adherence and outcome, but preferences regarding different drug formulations have been rarely assessed. To explore attitudes toward different drug formulations in a cross-sectional study in psychiatric patients and a comparison group of healthcare professionals. Inpatients (n = 59, age 46 ± 14 years, 63% female) and staff members (n = 96, age 40 ± 10 years, 65% female) of a psychiatric department were surveyed using a questionnaire on attitudes toward 18 possible application forms of psychotropic drugs including newer formulations such as fast-dissolving tablets. The questionnaire asked respondents to rate …

PharmacologyDrugOlanzapinemedicine.medical_specialtybusiness.industrymedia_common.quotation_subjectAlternative medicineMedication adherencePharmacyPharmacologyPreferencePsychotropic drugmedicineZiprasidonebusinessmedia_commonmedicine.drugClinical psychologyAmerican Journal of Drug Delivery
researchProduct

Effects of dopamine infusion on plasma catecholamines in preterm and term newborn infants.

1991

Newborn infants (21 preterm and 13 term) received dopamine infusions at a low (2.5-3.4 micrograms/kg per min) and/or high (5-10 micrograms/kg per min) infusion rate and changes in plasma catecholamines were monitored. The mean baseline values for dopamine, noradrenaline and adrenaline were between 240 and 560, 125 and 144 and 62 and 82 pg/ml, respectively. During low-rate infusion of dopamine, there was a significant increase in plasma dopamine (20-100 fold), noradrenaline (three- to five-fold) and adrenaline (threefold). Administration of dopamine at the high rate resulted in an even larger increase in the plasma catecholamines (dopamine, 100-300 fold; noradrenaline, seven- to eightfold; a…

Baseline valuesHigh ratemedicine.medical_specialtyDose-Response Relationship DrugEpinephrinebusiness.industryDopamineInfant NewbornNorepinephrine (medication)NorepinephrineEpinephrineEndocrinologyDopamineInternal medicinePediatrics Perinatology and Child HealthPlasma concentrationmedicineCatecholamineHumansbusinessPerfusionInfant Prematuremedicine.drugEuropean journal of pediatrics
researchProduct

Amplifying effect of serotonin on contractile responses in rat aorta and depletion of intracellular Ca-stores

1993

1. Serotonin, 1 microM, induces a contractile response in isolated rat aorta in the presence or absence of extracellular Ca. 2. In Ca-free media, the fast phasic contraction is lower in magnitude and further addition of serotonin evokes no response. 3. Recovery of the contractile response in Ca-free medium is obtained by a 40 min incubation in Ca-containing solution. 4. In Ca, Mg-free medium, the response to serotonin is significantly higher than that obtained in the presence of Mg. 5. An amplifying effect of serotonin on the contractile responses induced by serotonin itself or by noradrenaline was observed in Ca-containing but not in Ca-free solution.

MaleSerotoninmedicine.medical_specialtychemistry.chemical_elementAorta ThoracicIn Vitro TechniquesCalciumBiologyMuscle Smooth VascularNorepinephrine (medication)NorepinephrineInternal medicinemedicine.arterymedicineExtracellularAnimalsMagnesiumRats WistarPharmacologyCalcium metabolismAortaAcetylcholineRatsEndocrinologychemistryCatecholamineCalciumSerotoninmedicine.symptomMuscle Contractionmedicine.drugMuscle contractionGeneral Pharmacology: The Vascular System
researchProduct

Medication-related osteonecrosis of the jaws. A large multicentric case-and-control retrospective review

2019

Medication-related osteonecrosis of the jaws retrospective review
researchProduct

Sustained low-efficiency dialysis (SLED) for acute lithium intoxication

2008

Acute lithium intoxication may cause serious neurologic and cardiac manifestations, up to the patient's death. Owing to its low molecular weight, relatively small volume of distribution close to that of total body water, and its negligible protein binding, lithium can be efficiently removed by any extracorporeal modality of renal replacement therapy (RRT). However, the shift from the intracellular to the extracellular compartment, with the inherent rebound phenomenon after the end of RRT, might limit the efficacy of the conventional, short-lasting haemodialysis. There have been no published studies up to now concerning the use of sustained low-efficiency dialysis (SLED) in lithium intoxicat…

Bradycardiamedicine.medical_specialtyLithium (medication)medicine.medical_treatmentCase Reportchemistry.chemical_compoundOliguriamedicineRenal replacement therapyDialysisbipolar disorderTransplantationbusiness.industryLithium carbonateGastric lavagedrug toxicitypsychotropic drugsSurgerychemistrylithiumNephrologyAnesthesiadialysisHemodialysismedicine.symptombusinessmedicine.drugClinical Kidney Journal
researchProduct